Recently, according to a report by Law360, 50 US congress members are urging the Food and Drug Administration (FDA) to end its review of e-cigarette applications that have been delayed by almost two years. They are also requesting the FDA to increase efforts to remove illegal e-cigarette products from the market.
In a letter addressed to FDA commissioner Robert Califf, these lawmakers are demanding that the FDA complete its review of pending applications for e-cigarette products and reject all non-tobacco flavored e-cigarette products, including menthol. Additionally, they are urging the FDA to utilize its existing enforcement tools to remove all synthetic nicotine products from the market, including those that are currently undergoing the application process.
Original text of the letter | Photo source: Diana DeGette
Advocating for children's health, urging the FDA to strengthen law enforcement.
Lawmakers are making an appeal due to the FDA's failure to complete the review of all pending e-cigarette applications by the court-mandated deadline of September 9, 2021.
The author of the letter, Diana DeGette, stated in a release that the FDA has repeatedly delayed removing flavored e-cigarettes from the market which poses a danger to children's health. She urged the FDA to strengthen enforcement on these harmful products and immediately take them down. Lawmakers believe:
These products pose a greater risk to the health of young people with each passing day they remain on the market.
The FDA needs to expedite the review of pending applications.
Even though the Food and Drug Administration (FDA) has completed reviews of many e-cigarette products, they have yet to finish countless pending applications, including those for popular products from well-known brands such as Juul Labs, Reynolds, and Smok.
Members of parliament are urging the FDA to complete the review of all pending applications no later than December 31, 2023, to ensure the safety and compliance of e-cigarette products.
Reference:
US legislators urge FDA to complete electronic cigarette applications.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
